Effect of edaravone dexborneol combined with compound troxerutin on treatment of patients with acute progressive cerebral infarction
Wang Fei
Kang Jian
Chen Xufeng
Liu Hui
Abstract：Objective To observe the effect of edaravone dexborneol combined with compound troxerutin on treatment of patients with acute progressive cerebral infarction(APCI).Methods A total of 102 patients with APCI who were treated in the Qixia District Hospital in Nanjing from June 2022 to June 2024 were enrolled in the study and randomly divided into the con-trol group and the observation group,with 51 cases in each group.The treatment regimen for the control group:patients received edaravone dexborneol;the treatment regimen for the observation group:patients received edaravone dexborneol combined with compound troxerutin.The neurological function,daily living ability,inflammatory factors,hemorheological indicators and adverse reactions were observed and compared between the two groups.Results The NIHSS scores of the observation group and the con-trol group were respectively(11.05±3.24)points and(13.77±3.13)points after the treatment for 14 days,lower than(22.47±5.51)points and(21.88±5.47)points before the treatment.The MBI of the observation group and the control group was respectively(57.83±13.76)points and(49.45±13.51)points after the treatment for 14 days,higher than(27.14±7.28)points and(26.85±6.34)points before the treatment.Moreover,the change amplitude of the observation group was greater than that of the control group(t=12.759,9.190,-14.079,-10.815,-4.312,3.103,P<0.05).The effective rate of treatment of the observation group was 90.20%,higher than 62.75%of the control group,and there was significant difference(χ2=10.679,P<0.05).The levels of hs-CRP and TNF-α of the ob-servation group and the control group were respectively(4.27±0.78)mg·L-1,(6.91±1.21)mg·L-1,(16.11±3.67)ng·L-1 and(23.02±3.46)ng·L-1 after the treatment for 14 days,lower than(13.74±1.15)mg·L-1,(13.40±1.52)mg·L-1,(71.84±7.25)ng·L-1 and(72.04±7.56)ng·L-1 before the treatment;the levels of the above indexes of the observation group were lower than those of the control group,and there were significant differences(t=44.760,23.856,48.978,42.106,-12.108,-9.784,P<0.05).The levels of PSV,FIB and HSV of the observation group and the control group were respectively(1.05±0.24)mPa·s,(1.77±0.13)mPa·s,(2.73±0.76)g·L-1,(3.15±0.5)g·L-1,(4.98±0.94)mPa·s and(5.88±0.76)mPa·s after the treatment for 14 days,lower than(2.47±0.52)mPa·s,(2.51±0.47)mPa·s,(4.14±0.28)g·L-1,(4.25±0.34)g·L-1,(6.78±1.23)mPa·s and(6.53±1.31)mPa·s before the treatment;moreover,the levels of the above indexes of the observation group were lower than those of the control group,and there were significant differ-ences(t=-18.838,-3.277,-5.317,all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(13.73%vs 17.65%)(χ2=0.297,P=0.586).Conclusion Edaravone dexborneol combined with compound troxerutin enhances the therapeutic efficacy of APCI,improves neurological function and hemorheology and reduces inflammation,without in-creasing the risk of adverse reactions.
Keywords：Acute progressive cerebral infarctionEdaravone dexborneolCompound troxerutinEfficacy
Publication Date：2025-06-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 416-420 )